← All trials
NCT03101800
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 14, 2016
- Primary completion
- Dec 14, 2018
- Completion date
- Dec 14, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 84
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of CopenhagenLead sponsor
- Hospitalsenhed MidtCollaborator
- University Hospital KogeCollaborator
- University of CopenhagenCollaborator
- University of Southern DenmarkCollaborator
- Aalborg UniversityCollaborator
- Aarhus UniversityCollaborator
- University of CopenhagenReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.